When PD-1 binds to its ligand, PD-L1, the two recruits, SHP2, generate inhibitory signals and inhibit the PI3K/AKT/mTOR and RAS/MEK/ERK1/2 pathways, thereby inhibiting the activation of T cells and helping the immune escape of cancer cells [32, 33]. Here, MTOR is linked to cancer.